BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight

Group 1 - Teva Pharmaceuticals Industries Limited is identified as one of the most undervalued stocks in the pharmaceutical sector, with analysts expressing confidence in its growth potential [1][2] - Bank of America Securities analyst Jason Gerberry has reaffirmed a Buy rating on TEVA and raised the price target to $32.00, indicating belief in the stock's undervaluation relative to its improving revenue and debt reduction [1][3] - Barclays analyst Glen Santangelo initiated coverage of TEVA with an Overweight rating and a price target of $35.00, reflecting Wall Street's confidence in Teva's branded growth drivers and strategic progress [2][3] Group 2 - Teva has made significant advancements in its pipeline, including the submission of a New Drug Application (NDA) to the U.S. FDA for olanzapine long-acting injectable for schizophrenia, based on positive Phase 3 trial data [3] - The approval of this new drug would enhance Teva's branded neuroscience franchise, complementing its existing product UZEDY [3][4] - Teva is recognized as a global leader in the pharmaceutical industry, with a strong generics business and a growing portfolio of specialty and innovative medicines [4]